Previous Close | 53.78 |
1-Year Change | 141.82% |
6-Months Change | 56.61% |
3-Months Change | 18.28% |
Moving Avg (50d) | 46.445 |
Moving Avg (200d) | 39.501 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 3.01B |
Beta (3-Years) | 1.36 |
Revenue Growth (ttm) | 141.99% |
Net Profit Margin (ttm) | -913.95% |
Return On Assets (ttm) | -21.8% |
EPS (ttm) | -3.95 |
PE Ratio (ttm) | -13.62 |
Dividend Yield | % |
Asset Description: | Agios Pharmaceuticals, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2024-11-20 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
54.566 | 52.896 | 51.782 | 50.112 | 47.328 | 44.544 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |